NDA.FI

15.87

+0.13%↑

DIM

162.25

+4.14%↑

BKT

13.852

+0.22%↑

FCFS

225.07

+1.44%↑

RAND

25.255

+0.28%↑

NDA.FI

15.87

+0.13%↑

DIM

162.25

+4.14%↑

BKT

13.852

+0.22%↑

FCFS

225.07

+1.44%↑

RAND

25.255

+0.28%↑

NDA.FI

15.87

+0.13%↑

DIM

162.25

+4.14%↑

BKT

13.852

+0.22%↑

FCFS

225.07

+1.44%↑

RAND

25.255

+0.28%↑

NDA.FI

15.87

+0.13%↑

DIM

162.25

+4.14%↑

BKT

13.852

+0.22%↑

FCFS

225.07

+1.44%↑

RAND

25.255

+0.28%↑

NDA.FI

15.87

+0.13%↑

DIM

162.25

+4.14%↑

BKT

13.852

+0.22%↑

FCFS

225.07

+1.44%↑

RAND

25.255

+0.28%↑

Home・Akcijų sąrašas・Ipsen SA.

Search

Ipsen SA.

Uždarymo kaina

SektoriusFinansų sektorius

169.65 1.95

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

166.4

Max

169.75

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-225M 110M
Pardavimai	36M 1.9B
P/E Sektoriaus vid.	30.904 37.736
Dividendų pajamingumas	0.86
Pelno marža	5.899
Darbuotojai	5,535
EBITDA	-171M 466M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-13.77% downside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	0.86% 4.66%
Kitas uždarbis	2026-07-30

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2.2B 14B
Ankstesnė atidarymo kaina	167.7
Ankstesnė uždarymo kaina	169.65

Naujienos nuotaikos

By Acuity

16%

84%

25 / 439 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

99.85 / 104 Palaikymas ir pasipriešinimas

Ipsen SA. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-04 22:17; UTC

Uždarbis

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

2026-05-04 23:47; UTC

Uždarbis

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

2026-05-04 23:45; UTC

Uždarbis

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

2026-05-04 23:45; UTC

Uždarbis

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

2026-05-04 23:40; UTC

Rinkos pokalbiai

Gold Steady Amid Likely Technical Recovery -- Market Talk

2026-05-04 22:44; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Jim Beyer To Be Chief Executive of Combined Company

2026-05-04 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

2026-05-04 22:42; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

2026-05-04 22:42; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

2026-05-04 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

2026-05-04 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Pro Forma Market Capitalization About A$10.7 Billion

2026-05-04 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Shareholders to Own About 51% of Combined Company

2026-05-04 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Board Unanimously Endorsed, Supported Deal

2026-05-04 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Deal Unanimously Recommended by Vault Board

2026-05-04 22:39; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

2026-05-04 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Regis Resources to Acquire All Ordinary Shares in Vault

2026-05-04 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Regis Resources, Vault Minerals Agree to Merger of Equals

2026-05-04 22:37; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

2026-05-04 22:26; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

2026-05-04 22:02; UTC

Uždarbis

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

2026-05-04 22:00; UTC

Rinkos pokalbiai

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

2026-05-04 21:52; UTC

Uždarbis

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

2026-05-04 21:50; UTC

Uždarbis

Westpac: Some Sectors More Affected Than Others>WBC.AU

2026-05-04 21:50; UTC

Uždarbis

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

2026-05-04 21:49; UTC

Uždarbis

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

2026-05-04 21:44; UTC

Uždarbis

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

2026-05-04 21:44; UTC

Uždarbis

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

2026-05-04 21:43; UTC

Uždarbis

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

2026-05-04 21:41; UTC

Uždarbis

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

2026-05-04 21:40; UTC

Uždarbis

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Akcijų palyginimas

Kainos pokytis

Ipsen SA. Prognozė

Kainos tikslas

By TipRanks

-13.77% į apačią

12 mėnesių prognozė

Vidutinis 144 EUR -13.77%

Aukščiausias 170 EUR

Žemiausias 130 EUR

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ipsen SA. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

4 ratings

1

Pirkti

3

Laikyti

0

Parduoti

Remiantis 4 analitikų, pateikusių Ipsen SA. akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

99.85 / 104Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Rinkos nuotaikos

By Acuity

25 / 439 reitingas Finansų sektorius

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Kitos sektoriaus akcijos

NDA.FI

Nordea Bank Abp

15.87

DIM

Sartorius Stedim Biotech.

162.25

BKT

Bankinter SA

13.852

FCFS

FirstCash Inc

225.07

RAND

Randstad Holding NV

25.255

Live chat